Professor

Speciality Interests

Liver cancer, biliary tract cancer

Schedule

schedule of week
05 MON
20
TUE
21
WEN
22
THU
23
FRI
24
AM available
PM available

Medical School

1998~2001 Ph.D. in Medicine Department of Pathology, Korea University College of Medicine, Seoul, Korea Awarded Ph.D. degree in Medicine 1978~1984 Master of Science Department of Medicine, Yonsei University College of Medicine, Seoul, Korea Awarded M.D. degree in Medicine

Specialty Training

Specialty Training
Fellowship   Yonsei Cancer Center, Yonsei University Severance Hospital
Residency   1985~1988 Yonsei University Severance Hospital
Internship   1984~1985 Yonsei University Medical Center, Seoul, Korea

Other Education

  • 2010~2011 Director Strategic Business Development Office of strategy & Planning Samsung Healthcare Group
    2009~2011 Head Division of Hematology-Oncology, Department of Medicine Samsung Medical Center
    2007~2010 Executive Director Samsung Clinical Research Institute
    2006~present Professor Division of Hematology-Oncology, Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea
    2003~2006 Director Clinical Research Center, Ajou University School of Medicine Suwon, Korea
    2001~2006 Chairman Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
    2004~2006 Professor Department of Hematology-Oncology, Ajou University School of Medicine
    2000~2004 Associate Professor Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
    1995~1997 Postdoctoral fellow Johns Hopkins University Oncology Center, Brady Urological Institute Baltimore, MD, U.S.A.
    1995~2000 Assistant Professor Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
    1993~1995 Instructor Department of Hematology-Oncology, Ajou University School of Medicine Suwon, Korea
    1991~1993 Research Instructor Oncology Division, Yonsei Cancer Center, Department of Internal medicine, Yonsei University College of Medicine Seoul, Korea

Participation in Academic Societies
and Research

  • Member Korean Association for Clinical Oncology
    Member Korean Cancer Association
    Member Korean Association of Internal Medicine
    Member Korean Medical Association
    Member Korean Cancer Study Group
    Active member AACR (American Association of Cancer Research)
    Active member ASCO (American Society of Clinical Oncology)

Thesis

BRIT J CANCER 2021 10.1038/s41416-021-01380-3

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

Ryoo1, BY; Cheng, AL; Ren, ZG; Kim, TY; Pan, HM; Rau, KM; Choi, HJ; Park, JW; Kim, JH; Yen, CJ; Lim, HY; Zhou, DL; Straub, J; Scheele, J; Berghoff, K; Qin, SK

ADV THER 2021 10.1007/s12325-021-01700-2

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein >= 400 ng/mL: A Matching-Adjusted Indirect Comparison

Trojan1, J; Mollon, P; Daniele, B; Marteau, F; Martin, L; Li, YX; Xu, Q; Piscaglia, F; Zaucha, R; Sarker, D; Lim, HY; Venerito, M

LIVER CANCER 2021 10.1159/000515553

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Kudo1, M; Lim, HY; Cheng, AL; Chao, Y; Yau, T; Ogasawara, S; Kurosaki, M; Morimoto, N; Ohkawa, K; Yamashita, T; Lee, KH; Chen, ER; Siegel, AB; Ryoo, BY

EUR UROL 2021 10.1016/j.eururo.2020.12.029

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Motzer1, RJ; Russo, P; Haas, N; Doehn, C; Donskov, F; Gross-Goupil, M; Varlamov, S; Kopyltsov, E; Lee, JL; Lim, HY; Melichar, B; Zemanova, M; Rini, B; Choueirim, TK; Wood, L; Reaume, MN; Stenzl, A; Chowdhury, S; McDermott, R; Michael, A; Izquierdo, M; Aimone, P; Zhang, H; Sternberg, CN

ANN ONCOL 2021 10.1016/j.annonc.2020.11.017

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK

CLOSE

Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper care in a safe setting without discrimination nor should their right to care be violated regardless of their gender, age, religion, social status, nationality, language, race, or physical/mental/financial status. Medical teams shall not refuse to provide care without justifiable reason.

2. Right to be informed and to make an autonomous decision

Patients have the right to obtain full and complete information from their medical team, to ask questions, and to determine their agreement or refusal concerning: diagnosis, treatment (purpose, plans and methods), outcomes of care (including unanticipated outcomes), discharge plan, participation in medical research studies, organ transplantation/donation, etc. Within ethical boundaries, patients may discontinue or refuse treatment, request that the medical team explain and suggest alternative treatments, and reserve the right to make their own decisions.

3. Right to confidentiality

Patients' rights to confidentiality regarding their physical/health status and privacy will not be violated. Patients can expect that all medical records/reports and their personal privacy will be kept confidential unless the patient has given consent or disclosure is permitted by law. To ensure their privacy, patients may be informed that Individuals not directly involved in their care may not be present and that the number of guardians accompanying patients to consultation rooms may be limited.

4. Right to request consultation and mediation

In the event of a medical dispute, patients may request consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency).

5. Right to have values and beliefs respected

Patients will not be discriminated against because of their culture, religious values, or beliefs, and their rights will not be violated.

6. Right to receive care in a safe setting

Patients have the right to receive hospital-provided care where the patient’s medical information is protected and patient safety can be assured. In addition, patients have the right to be protected from possible dangers that can occur in a hospital and to have stability of mind and body.

Patients' Responsibilities

1. Responsibility to trust and respect the medical team

Patients must accurately inform the medical team of their health condition and must trust and respect the medical team's treatment plan. Patients may be responsible for consequences that result from not following instructions.

2. Responsibility to not use dishonest methods for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest methods, such as seeking medical care under disguised ownership.

3. Responsibility to abide by all hospital regulations

Patients are expected to treat all hospital staff and other patients with courtesy and respect; to abide by all hospital rules; and to earnestly fulfill their financial obligation to the hospital. Also, patients and their family members are expected to participate in all safety regulations.